Shareholders of Shanghai Bio-heart Biological Technology (HKG:2185) will meet Feb. 13 to vote on the proposed 155.6 million yuan capital injection into unit Zhejiang Bioheart Medical Equipment, a Thursday bourse filing said.

The parties had agreed on earlier in January that Jiaxing Guojian Baixin Equity Investment Partnership Enterprise would make the investment in exchange for a 45.3208% stake in Zhejiang Bioheart.

Price (HKD): $1.55, Change: $+0.010, Percent Change: +0.65%